Humedix Co Ltd
KOSDAQ:200670
Operating Margin
Humedix Co Ltd
Operating Margin represents how efficiently a company is able to generate profit through its core operations.
Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.
Operating Margin Across Competitors
| Country | Company | Market Cap |
Operating Margin |
||
|---|---|---|---|---|---|
| KR |
H
|
Humedix Co Ltd
KOSDAQ:200670
|
781.7B KRW |
27%
|
|
| US |
|
Eli Lilly and Co
NYSE:LLY
|
765.6B USD |
40%
|
|
| UK |
|
Dechra Pharmaceuticals PLC
LSE:DPH
|
440.4B GBP |
3%
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
403.3B USD |
26%
|
|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
2T DKK |
45%
|
|
| CH |
|
Roche Holding AG
SIX:ROG
|
207.3B CHF |
33%
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
180.2B CHF |
33%
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
167.5B GBP |
24%
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
213.1B USD |
34%
|
|
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
183.8B USD |
11%
|
|
| US |
|
Pfizer Inc
NYSE:PFE
|
141B USD |
27%
|
Humedix Co Ltd
Glance View
Humedix Co., Ltd. engages in the manufacture and sale of hyaluronic acid based medical devices and arthritis treatment products. The company is headquartered in Seongnam, Gyeonggi-Do. The company went IPO on 2014-12-26. The firm distributes its products within domestic market and to overseas markets
See Also
Operating Margin represents how efficiently a company is able to generate profit through its core operations.
Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.
Based on Humedix Co Ltd's most recent financial statements, the company has Operating Margin of 27.3%.
You don't have any saved screeners yet